Skip to content
6-K

Foreign Interim / Material

Mesoblast Limited MEOBF MESO

0001345099-26-000027

← back to feed
Filed
Feb 27, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted 2025 · Dec 31, 2025 1.29B sh
Shares Diluted 2024 · Dec 31, 2024 1.14B sh
Operating Cash Flow 2025 · Dec 31, 2025 −$30.34M
Operating Cash Flow 2024 · Dec 31, 2024 −$20.66M
Cash And Equivalents 2025 · Dec 31, 2025 $129.98M
Cash And Equivalents 2025 · Jun 30, 2025 $161.55M
Cash And Equivalents 2024 · Dec 31, 2024 $38.03M
Cash And Equivalents 2024 · Jun 30, 2024 $62.96M
Stockholders Equity 2025 · Dec 31, 2025 $574.68M
Stockholders Equity 2025 · Jun 30, 2025 $597.44M
Stockholders Equity 2024 · Dec 31, 2024 $461.26M
Stockholders Equity 2024 · Jun 30, 2024 $480.36M
Current Liabilities 2025 · Dec 31, 2025 $128.07M
Current Liabilities 2025 · Jun 30, 2025 $102.63M
Total Liabilities 2025 · Dec 31, 2025 $207.62M
Total Liabilities 2025 · Jun 30, 2025 $187.24M
Current Assets 2025 · Dec 31, 2025 $202.48M
Current Assets 2025 · Jun 30, 2025 $204.35M
Total Assets 2025 · Dec 31, 2025 $782.31M
Total Assets 2025 · Jun 30, 2025 $784.68M
Eps Diluted 2025 · Dec 31, 2025 −$0.03
Eps Diluted 2024 · Dec 31, 2024 −$0.04
Eps Basic 2025 · Dec 31, 2025 −$0.03
Eps Basic 2024 · Dec 31, 2024 −$0.04
Sga Expense 2025 · Dec 31, 2025 $28.54M
Sga Expense 2024 · Dec 31, 2024 $18.01M
Rd Expense 2025 · Dec 31, 2025 $46.16M
Rd Expense restated 2024 · Dec 31, 2024 $5.09M
Net Income 2025 · Dec 31, 2025 −$40.16M
Net Income 2024 · Dec 31, 2024 −$47.93M
Cost Of Revenue 2025 · Dec 31, 2025 $7.6M
Cost Of Revenue 2024 · Dec 31, 2024 $0
Revenue 2025 · Dec 31, 2025 $51.34M
Revenue 2024 · Dec 31, 2024 $3.16M